

# Rose A Gubitosi-Klug

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5925546/publications.pdf>

Version: 2024-02-01

41  
papers

2,349  
citations

279798

23  
h-index

302126

39  
g-index

41  
all docs

41  
docs citations

41  
times ranked

3242  
citing authors

#	ARTICLE	IF	CITATIONS
1	Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study. <i>Diabetes Care</i> , 2022, 45, 659-665.	8.6	14
2	Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2405-e2416.	3.6	9
3	Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 509-518.	11.4	19
4	Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2022, 45, 1779-1787.	8.6	7
5	Risk Factors for Longitudinal Resting Heart Rate and Its Associations With Cardiovascular Outcomes in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2021, 44, 1125-1132.	8.6	6
6	Residual $\beta$ cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	42
7	Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1499-1505.	8.6	20
8	Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 436-445.	11.4	56
9	Long-Term Complications in Youth-Onset Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 416-426.	27.0	234
10	The First Genome-Wide Association Study for Type 2 Diabetes in Youth: The Progress in Diabetes Genetics in Youth (ProDiGY) Consortium. <i>Diabetes</i> , 2021, 70, 996-1005.	0.6	37
11	Pediatric Diabetic Retinopathy: Updates in Prevalence, Risk Factors, Screening, and Management. <i>Current Diabetes Reports</i> , 2021, 21, 56.	4.2	15
12	Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study. <i>Pediatric Diabetes</i> , 2020, 21, 923-931.	2.9	11
13	Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes</i> , 2020, 69, 1000-1010.	0.6	106
14	Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure. <i>Pediatric Diabetes</i> , 2020, 21, 575-585.	2.9	4
15	Risk Factors for Hearing Impairment in Type 1 Diabetes. <i>Endocrine Practice</i> , 2019, 25, 1243-1254.	2.1	5
16	Montelukast Prevents Early Diabetic Retinopathy in Mice. <i>Diabetes</i> , 2019, 68, 2004-2015.	0.6	22
17	Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough?. <i>Pediatric Diabetes</i> , 2019, 20, 743-749.	2.9	14
18	Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 875-882.	8.6	114

#	ARTICLE	IF	CITATIONS
19	Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. <i>World Journal of Hepatology</i> , 2019, 11, 761-772.	2.0	31
20	Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. <i>Diabetes Care</i> , 2018, 41, 2495-2501.	8.6	27
21	Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2017, 376, 1507-1516.	27.0	101
22	Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2017, 40, 1010-1016.	8.6	108
23	Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A <sub>1c</sub> Levels. <i>Annals of Internal Medicine</i> , 2017, 167, 95.	3.9	231
24	Barriers to participation in industry-sponsored clinical trials in pediatric type 2 diabetes. <i>Pediatric Diabetes</i> , 2017, 18, 574-578.	2.9	10
25	Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes Care</i> , 2017, 40, 1756-1762.	8.6	77
26	Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes Care</i> , 2017, 40, 94-100.	8.6	79
27	Expanding Treatment Options for Youth With Type 2 Diabetes: Current Problems and Proposed Solutions. <i>Diabetes Care</i> , 2016, 39, 323-329.	8.6	33
28	Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. <i>JAMA Ophthalmology</i> , 2016, 134, 137.	2.5	38
29	Proinflammatory Responses Induced by CD40 in Retinal Endothelial and Muller Cells are Inhibited by Blocking CD40-Traf2,3 or CD40-Traf6 Signaling. <i>Investigative Ophthalmology and Visual Science</i> , 2014, 55, 8590-8597.	3.3	23
30	The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Summary and Future Directions. <i>Diabetes Care</i> , 2014, 37, 44-49.	8.6	99
31	The Long-Term Effects of Type 1 Diabetes Treatment and Complications on Health-Related Quality of Life. <i>Diabetes Care</i> , 2013, 36, 3131-3138.	8.6	128
32	The Association of Skin Intrinsic Fluorescence With Type 1 Diabetes Complications in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2013, 36, 3146-3153.	8.6	49
33	Clinical and Technical Factors Associated with Skin Intrinsic Fluorescence in Subjects with Type 1 Diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 466-474.	4.4	41
34	Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions. <i>Diabetes</i> , 2013, 62, 3976-3986.	0.6	215
35	Leukocytes regulate retinal capillary degeneration in the diabetic mouse via generation of leukotrienes. <i>Journal of Leukocyte Biology</i> , 2013, 93, 135-143.	3.3	39
36	Marrow-Derived Cells Regulate the Development of Early Diabetic Retinopathy and Tactile Allodynia in Mice. <i>Diabetes</i> , 2012, 61, 3294-3303.	0.6	79

#	ARTICLE	IF	CITATIONS
37	Increased Synthesis of Leukotrienes in the Mouse Model of Diabetic Retinopathy. , 2010, 51, 1699.		50
38	5-Lipoxygenase, but Not 12/15-Lipoxygenase, Contributes to Degeneration of Retinal Capillaries in a Mouse Model of Diabetic Retinopathy. Diabetes, 2008, 57, 1387-1393.	0.6	120
39	L1 cell adhesion molecule is neuroprotective of alcohol induced cell death. NeuroToxicology, 2007, 28, 457-462.	3.0	14
40	Idiopathic Short Stature. Endocrinology and Metabolism Clinics of North America, 2005, 34, 565-580.	3.2	22
41	Drugs and hormones used to treat pediatric and adolescent reproductive endocrine disorders. Pediatric Endocrinology Reviews, 2004, 2 Suppl 1, 93-107.	1.2	0